Fulcrum Therapeutics (FULC) Projected to Post Earnings on Tuesday

Fulcrum Therapeutics (NASDAQ:FULC) will likely be releasing its earnings data before the market opens on Tuesday, February 25th. Analysts expect Fulcrum Therapeutics to post earnings of ($0.28) per share for the quarter. Persons interested in registering for the company’s earnings conference call can do so using this link.

Fulcrum Therapeutics Stock Performance

NASDAQ:FULC opened at $3.86 on Monday. Fulcrum Therapeutics has a 52 week low of $2.86 and a 52 week high of $13.70. The firm has a market cap of $207.94 million, a price-to-earnings ratio of -12.44 and a beta of 2.03. The firm’s 50-day simple moving average is $4.18 and its 200 day simple moving average is $4.70.

Wall Street Analyst Weigh In

A number of research firms recently commented on FULC. HC Wainwright reaffirmed a “neutral” rating and set a $4.00 price target on shares of Fulcrum Therapeutics in a research report on Thursday, November 14th. Royal Bank of Canada reiterated a “sector perform” rating and set a $4.00 price objective on shares of Fulcrum Therapeutics in a research note on Thursday, November 14th. One research analyst has rated the stock with a sell rating, six have issued a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $9.33.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.